Illumina
Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company provides integrated systems, consumables, and analysis tools that enable researchers and clinicians to study genetic variation and biological function. Its core value proposition lies in accelerating the adoption of precision medicine through high-throughput, cost-effective genomic technologies.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Sequencing
primaryProvides platforms and reagents for determining the order of nucleotide bases in DNA samples, supporting applications from whole-genome sequencing to targeted gene panels. This segment includes the company's proprietary sequencing by synthesis (SBS) biochemistry and informatics suites.
NovaSeq X Plus, MiSeq i100, XLEAP-SBS, BaseSpace Informatics Suite, DRAGEN Bio-IT Platform, Illumina Connected Analytics, Emedgene
Genomic research centers, Academic institutions, Pharmaceutical companies, Commercial molecular diagnostic laboratories
Consumables and Services
majorOffers library preparation kits, sequencing reagents, and laboratory services including whole-genome sequencing and NIPT. This segment supports the ongoing operation of the installed base of instruments and provides sample-to-answer solutions.
Illumina Single Cell 3’ RNA Prep, Illumina Protein Prep, Illumina 5-base solution, TruSight Comprehensive Oncology panel
Hospitals, Biotechnology companies, Clinical laboratories
Arrays
minorUtilizes proprietary BeadArray technology for large-scale analysis of genetic variation, including SNP genotyping and methylation analysis. These solutions are used for high-throughput screening in agrigenomics, disease risk, and large-scale research studies.
iScan System, NextSeq 550 System, BeadArray
Agrigenomics researchers, Consumer genomics companies, Government laboratories
Segment Financials
Sequencing — Total Revenue
View metricUnited States and Canada — Total Revenue
View metricService — Total Revenue
View metricMicroarray — Total Revenue
View metricAsia-Pacific — Total Revenue
View metricBusiness Overview
Competitive Position
Illumina is the dominant market leader in next-generation sequencing (NGS), characterized by a massive installed base and a high-margin recurring revenue stream from proprietary consumables.
Geographies
North America, Europe, Asia-Pacific, China, Latin America
Customer Segments
Academic and Government, Biopharma, Clinical Diagnostics, Applied Markets
Upstream Dependencies
Chemical and biochemical material suppliers, Electronic component manufacturers, Single-source raw material providers, Cloud infrastructure providers
Downstream Customers
Academic research institutions, Clinical diagnostic labs, Pharmaceutical R&D departments, Agricultural biotechnology firms, Direct-to-consumer genetic testing companies
Competitors & Partners
Competitors
Illumina FAQ
Common questions about Illumina
Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company provides integrated systems, consumables, and analysis tools that enable researchers and clinicians to study genetic variation and biological function. Its core value proposition lies in accelerating the adoption of precision medicine through high-throughput, cost-effective genomic technologies.
Illumina (ILMN) has a market capitalization of $21.4B and trades on NASDAQ.
Illumina generated $4.4B in trailing twelve-month revenue with net income of $853.0M, representing a net margin of 19.4%. Gross margin stands at 66.2%, with free cash flow of $974.0M. These figures are based on the Q1 2026 filing.
Illumina's key competitors include Thermo Fisher Scientific, Natera, Inc. Common Stock, Agilent Technologies Inc., and others. These companies compete in similar markets and product categories.
Illumina has approximately 9,300 employees.